PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer

K. Muro, H. Uetake, K. Tsuchihara, K. Shitara, K. Yamazaki, M. Ota, E. Oki, T. Sato, T. Naitoh, Y. Komatsu, T. Kato, K. Yamanaka, I. Mori, J. Soeda, M. Hihara, T. Yamanaka, K. Akagi, A. Ochiai, T. Yoshino

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)iv10
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume30
DOIs
Publication statusPublished - Jul 1 2019

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Muro, K., Uetake, H., Tsuchihara, K., Shitara, K., Yamazaki, K., Ota, M., Oki, E., Sato, T., Naitoh, T., Komatsu, Y., Kato, T., Yamanaka, K., Mori, I., Soeda, J., Hihara, M., Yamanaka, T., Akagi, K., Ochiai, A., & Yoshino, T. (2019). PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 30, iv10. https://doi.org/10.1093/annonc/mdz155.033